News of Note—Dr. Reddy’s and FDA; Divi’s Labs plant cleared; SK Capital completes Perrigo API deal

News of note from pharma manufacturing.

> Dr. Reddy’s in a filing said it will ask the FDA to reinspect its formulations plant in Duvvada in 2018. Announcement (PDF)

> India’s Divi’s Laboratories said in a filing with the Bombay Stock Exhange that the FDA has issued an Establishment Inspection Report for its Unit-II in Visakhapatnam, which had earlier received a Form 483 with six observations. Release (PDF)

> SK Capital has completed its $110 million buyout of Perrigo’s API business. Release | FiercePharma article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.